Skip to content
Life Sciences Series A Founded 2016

Vaxinano

Vaxinano is engaged in the development of prophylactic and therapeutic vaccines for infectious diseases, for human and animal health markets. The company is using nanoparticles made of starch and lipids (nanovectors) to develop vaccines. The company's experimental vaccines target toxoplasmosis and tuberculosis and developing anti-bacterial, antiviral and antiparasitic vaccines. The company operates in the Infectious…

📍 Lille, France · Infectious Diseases,

Funding snapshot

Last roundSeries A
Amount$6M
Date29 October 2024
Total raised$6M
Team size13

About

Vaxinano is engaged in the development of prophylactic and therapeutic vaccines for infectious diseases, for human and animal health markets. The company is using nanoparticles made of starch and lipids (nanovectors) to develop vaccines. The company's experimental vaccines target toxoplasmosis and tuberculosis and developing anti-bacterial, antiviral and antiparasitic vaccines. The company operates in the Infectious Diseases sector with additional focus on Infectious Diseases and Immunotherapy. Its business model centers on Vaccine. Founded in 2016, headquartered in Lille, France. The company has raised $6.5M at the Series A stage. Backed by investors including TCD Capital, Nord France Amorquage, WiSEED, Bpifrance, Captechsantenutrition and others.

Business model

Nanotechnology > Nanoenabled Products > Life Science > Drug Delivery > Vaccine,

Infectious Diseases > Drugs > Diversified,

Drug Delivery > Nanoparticle Based

Team background

College Wise > HEC Paris

Institutional investors

TCD Capital Nord France Amorquage WiSEED Bpifrance Captechsantenutrition ANR

Latest coverage

No articles yet.

Raising like Vaxinano?

Analyze your pitch deck before your next raise.

Analyze My Deck →